Related Experiment Video
Updated: Jun 4, 2025
08:14
Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial
Published on: September 29, 2015
12.9K
Application of i-PRF in dentistry.
Wojciech Niemczyk1, Stanisław Niemczyk2, Olga Odrzywolska1
1FACULTY OF MEDICAL SCIENCES IN ZABRZE, MEDICAL UNIVERSITY OF SILESIA, ZABRZE, POLAND.
Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|December 23, 2024
Summary
Injectable platelet-rich fibrin (i-PRF) promotes tissue regeneration in dentistry. This anticoagulant-free concentrate offers enhanced healing in periodontology, oral surgery, and orthodontics.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Dental Applications
Background:
- Injectable platelet-rich fibrin (i-PRF) is a novel platelet concentrate for tissue regeneration.
- Unlike platelet-rich plasma (PRP), i-PRF is anticoagulant-free, cost-effective, and easy to handle.
- Developed in 2014, i-PRF transforms into a growth factor-rich clot over 10-14 days.
Purpose of the Study:
- To review the efficacy of i-PRF in various dental applications.
- To highlight i-PRF's potential in promoting tissue regeneration and healing.
- To compare i-PRF with other regenerative treatments.
Main Methods:
- Review of existing literature on i-PRF applications in dentistry.
- Analysis of i-PRF's properties and procedural aspects.
- Evaluation of clinical outcomes in periodontology, oral surgery, orthodontics, and endodontics.
Main Results:
- i-PRF effectively treats periodontitis, enhancing gingival thickness and reducing inflammation.
- It promotes bone regeneration in oral surgery and accelerates tooth movement in orthodontics.
- Limited studies suggest i-PRF supports revascularization and periapical healing in endodontics.
Conclusions:
- i-PRF exhibits significant regenerative, anti-inflammatory, and antimicrobial potential in dentistry.
- Its ease of use and cost-effectiveness make it a promising therapeutic agent.
- Further research and clinical application of i-PRF are warranted.
More Related Videos
Related Concept Videos
01:22Formation of the Platelet Plug
4.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
4.2K
01:16Clot Retraction and Fibrinolysis
3.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.8K
01:05Introduction to Hemostasis
5.5K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
5.5K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
467
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
467
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
608
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
608